Skip to main content
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Articles published by Biomea Fusion, Inc.

< Previous 1 2 Next >
Late-Breaker Oral Presentation Showing New Analysis from the Escalation Portion of COVALENT-111 Presented at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Presents Preclinical Data Showing Icovamenib (BMF-219) Enhanced Effectiveness of GLP-1-Based Therapies and Introduces BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist Candidate
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports Third Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Approval of “icovamenib” as International Nonproprietary Name for BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion to Host Conference Call and Webcast on Wednesday, October 30th at 4:30 pm ET to Announce Our Lead Clinical Candidate, BMF-650, a Next-Generation, Oral Small-Molecule GLP-1 Receptor Agonist and Preclinical Data Combining BMF-219 with a GLP-1
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion to Present at the 1st Annual Asian Conference on Innovative Therapies for Diabetes Management (ATTD-ASIA 2024)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Announces Formation of Global Scientific Advisory Board with 22 World-Renowned Diabetes Experts
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
FDA Lifts Clinical Hold on BMF-219 in Type 2 and Type 1 Diabetes Trials
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports Second Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces BMF-219 in Diabetes Placed on Clinical Hold
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grant under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Completion of Enrollment of First 3 Arms in Phase 2 Expansion Cohorts of COVALENT-111 Study for BMF-219 in Type 2 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports First Quarter 2024 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Highlights Initial Data from the First Two Type 1 Diabetes Patients Dosed with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Reports Fourth Quarter and Full Year 2023 Financial Results and Corporate Highlights
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Presents Patient Cohorts in COVALENT-111 Displaying a Durable Placebo-Adjusted Mean Reduction of up to 1.4% in HbA1c While Off Therapy at Week-26, after BMF-219’s 28-Day Treatment Cycle, Supporting Improved Pancreatic Function
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion, Inc. Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Highlights Recent Updates and Anticipated 2024 Corporate Milestones at 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Dosing of First Type 1 Diabetes Patient in Phase II Study (COVALENT-112) with BMF-219
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion to Present at the 42nd Annual J.P. Morgan Healthcare Conference
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Presents Achievement of Minimal Residual Disease Negativity (MRD-neg) in First Complete Responder from Ongoing Phase I Study (COVALENT-101) of BMF-219 in Patients with Relapsed or Refractory (R/R) Acute Myeloid Leukemia (AML) at the 2023 ASH
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Near Doubling the Percentage of Patients with Durable HbA1c Reduction in the 200 mg Dose Cohorts
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Presents Long-Term Follow-Up Data Showing Improved Glycemic Control after 22 Weeks Off Treatment in Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes in a Poster Presentation at the World Congress Insulin
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion to Present Long-Term Follow-Up Data from Ongoing Phase II Study (COVALENT-111) of BMF-219 in Adults with Type 2 Diabetes and Results from Ex-Vivo Human Islet Experiments at the World Congress Insulin Resistance, Diabetes & Cardiovascular
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Health Canada Clearance of Clinical Trial Application (CTA) for BMF-219 in Type 1 Diabetes
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
Biomea Fusion Announces Acceptance of Three Abstracts for its Novel Menin Inhibitor Highlighting Durable Glycemic Control in Diabetes Patients at the International Conference on Advanced Technologies & Treatments for Diabetes (ATTD) in 2024
From Biomea Fusion, Inc.
Via GlobeNewswire
Tickers BMEA
< Previous 1 2 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.